Schonfeld Strategic Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.25M | Buy |
147,923
+128,731
| +671% | +$3.7M | 0.03% | 554 |
|
|
2025
Q1 | $644K | Sell |
19,192
-426,754
| -96% | -$14.3M | ﹤0.01% | 1358 |
|
|
2024
Q4 | $22.8M | Sell |
445,946
-44,779
| -9% | -$2.29M | 0.13% | 116 |
|
|
2024
Q3 | $25.1M | Sell |
490,725
-162,832
| -25% | -$8.32M | 0.17% | 76 |
|
|
2024
Q2 | $29.3M | Buy |
653,557
+518,264
| +383% | +$23.2M | 0.19% | 86 |
|
|
2024
Q1 | $6.33M | Buy |
135,293
+68,000
| +101% | +$3.18M | 0.04% | 467 |
|
|
2023
Q4 | $2.39M | Sell |
67,293
-209,915
| -76% | -$7.47M | 0.02% | 683 |
|
|
2023
Q3 | $8.24M | Buy |
+277,208
| New | +$8.24M | 0.06% | 356 |
|
|
2023
Q2 | – | Sell |
-73,890
| Closed | -$1.19M | – | 2040 |
|
|
2023
Q1 | $1.19M | Buy |
+73,890
| New | +$1.19M | 0.01% | 875 |
|
|
2022
Q1 | – | Sell |
-18,600
| Closed | -$528K | – | 2432 |
|
|
2021
Q4 | $528K | Sell |
18,600
-2,900
| -13% | -$82.3K | ﹤0.01% | 1167 |
|
|
2021
Q3 | $453K | Sell |
21,500
-300
| -1% | -$6.32K | ﹤0.01% | 1244 |
|
|
2021
Q2 | $411K | Buy |
+21,800
| New | +$411K | ﹤0.01% | 1245 |
|